文献速递药物不良反应与药物警戒

不良事件随访在推进药物与疫苗安全认知中的作用:范围综述

The Role of Adverse Event Follow-Up in Advancing the Knowledge of Medicines and Vaccines Safety: A Scoping Review.
PubMed 文献 · Drug Saf · 2025-05-20

该范围综述检索2013至2023年MEDLINE与Embase文献及监管指南,纳入23项研究,评估药物警戒中不良事件随访的概念、实施方式、频率与价值。随访方式包括数字工具、电话和家访,应答率差异大;随访启动方以药物警戒中心为主,同意实践不一致,术语使用和方法学存在显著异质性。

要点

  • 电话随访应答率(62–89%)高于数字工具(29–31%)。
  • 随访启动方以药物警戒中心(44%)为主,学术界30%,上市许可持有人26%。
  • 随访术语不一致、研究场景多变,限制结果外推。

核心结论

  • 尽管所有药物警戒组织均使用随访且存在监管指南,但相关科学研究匮乏。
  • 随访率报告为19%至100%,术语使用不一致且研究方法与场景高度变异,限制普遍化。

研究设计与样本

  • 范围综述遵循2018年PRISMA-ScR扩展,方案注册于OSF。

主要发现

  • 数字工具(邮件、在线调查、短信)用于22%的研究,应答率29%至31%。
  • 电话随访用于17%的研究,应答率62%至89%。
  • 家访用于9%的研究,仅1项研究报告应答率为74%。
  • 35%的研究采用开放式随访(未指定预先确定的不良事件),22%聚焦特定不良事件或结局,43%为其他原因。
  • 随访启动方:学术界30%,药物警戒中心44%,上市许可持有人26%。

局限性

  • 随访术语使用不一致,研究方法和场景高度变异,限制结果普遍化。
  • 需进一步研究确定最受益于随访的报告和不良事件类型、问题数量与应答率的相关性及随访信息对报告可评估性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION AND OBJECTIVE: Adverse events (AEs) associated with medication and vaccine use are of significant concern in pharmacovigilance (PV), necessitating robust detection, documentation, and reporting mechanisms. The primary objective of this scoping review is to understand and evaluate the concept, implementation, frequency, and value of "follow-up" in the context of AE assessment. Secondary objectives include providing an overview of various definitions of "follow-up," describing the requirements and studies evaluating follow-up methods, and assessing how often follow-up is undertaken in assessing an AE, by whom, and its value. METHODS: This scoping review followed the 2018 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews. The protocol was registered on the Open Science Framework (OSF). The review included peer-reviewed literature and regulatory guidelines, the search strategy involved querying MEDLINE (via PubMed) and Embase for publications indexed from January 2013 to December 2023. The Rayyan® collaborative review platform was used to manage duplicates and select eligible studies. Data extraction was performed using a standardized template, and the extracted data were summarized descriptively. RESULTS: The search yielded 4,428 articles, with 23 studies meeting the inclusion criteria. Methods for follow-up varied among the studies, with digital tools such as emails, online surveys, and SMS utilized in 22% of the studies, achieving response rates ranging from 29 to 31%. Telephone follow-up was employed in 17% of studies, showing higher response rates between 62 and 89%. In settings with limited digital access, home visits were conducted in 9% of studies; only one study reported a response rate which was 74%. The nature of the follow-up approach was diverse: 35% of studies conducted open-ended follow-up, where no pre-determined AEs were specified, whilst 22% of studies focused on specific AEs or outcomes; the remaining 43% had other reasons such as deduplication, assessing informativeness, characterizing unlisted adverse drug reactions (ADRs) or were related to studies evaluating follow-up methods. The initiation of follow-up activities, including methodological research, was driven by academia in 30% of studies, PV centers in 44%, and marketing authorization holders (MAHs) in 26%. Consent practices varied across the studies: 39% of studies did not pre-consent individuals prior to requesting follow-up, while 31% secured consent to contact prior to follow-up, and the other 30% related to studies evaluating follow-up methods. CONCLUSION: Despite the use of follow-up across all PV organizations, and existing regulatory guidance, there is a dearth of scientific research on the topic. While rates of follow-up were quoted between 19 and 100% there is inconsistency in the use of the term, and huge variability in the way follow-up was studied and the scenarios in which it was studied, constraining the ability to generalize. Further research is needed to determine the optimal types of reports and AEs that benefit most from follow-up, the correlation between the number of questions asked and response rates, and the impact of follow-up information on the evaluability of AE reports.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Kara V, Van Hunsel F, Bate A, et al. The Role of Adverse Event Follow-Up in Advancing the Knowledge of Medicines and Vaccines Safety: A Scoping Review. Drug Saf. 2025. PMID: 40392520. doi:10.1007/s40264-025-01553-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。